Knee OsteoarthritisLeave blankNCT07769593
MORA Cure for Knee Osteoarthritis With Anterior Knee Pain
A study testing MORA Cure in people with Knee Osteoarthritis and Anterior Knee Pain, run by EverEx Inc. at 2 sites in South Korea.
Trial summary
This prospective, multicenter, single-arm, sponsor-initiated pilot study will evaluate the clinical course and safety of MORA Cure in adults older than 50 years with knee osteoarthritis accompanied by anterior knee pain. Participants will use MORA Cure for 8 weeks. Read more about this study
- Who is it for?
- Ages 51 years and older
- Conditions the study is for
- Knee Osteoarthritis, Anterior Knee Pain
- What is being tested?
- MORA Cure
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 44 participants
- Where
- 2 sitesSouth Korea
- Study dates
- 10 Jul 2026to 28 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 51 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults older than 50 years.
- Kellgren-Lawrence grade 1 or higher on weight-bearing plain radiographs of the study knee.
- Osteoarthritis-related pain in the study knee for at least 3 months.
- Anterior knee pain in the study knee involving the peripatellar, anterior patellar, or retropatellar region, with clear provocation or worsening of anterior knee pain during at least one patellofemoral joint-loading activity: stair ascent or descent, squatting, or rising from a chair.
- If medial, lateral, or posterior knee pain is also present, the participant is able to distinguish and separately report anterior knee pain.
- Voluntary written informed consent before study participation.
Who cannot join
- Acute injury of the study knee within the previous 3 months, including fracture, ligament tear, or meniscal tear requiring surgical treatment or immobilization.
- Injection therapy to the study knee within the previous 3 months.
- Current use of opioid analgesics for pain control.
- Does not own a smartphone or is unable to use the mobile application.
- Current participation in another clinical trial or planned participation in another clinical trial during this study.
- Diagnosed active inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, or reactive arthritis.
Show all 9Show fewer
- Acute attack of gout or pseudogout in the study knee within the previous 3 months.
- Previous total knee arthroplasty, corrective osteotomy, or other major surgery affecting knee alignment or joint structure in the study knee.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Trial locations and contacts
2 sites in 1 country.
South Korea2 sites
SMG-SNU Boramae Medical Center
Dongjak, Seoul, 07061
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, 13496
About this study
Official title: A Prospective, Multicenter, Single-Arm, Pilot Study to Evaluate the Clinical Outcomes and Safety of the Digital Therapeutic MORA Cure in Patients With Knee Osteoarthritis Accompanied by Anterior Knee Pain: 8-week
This prospective, multicenter, single-arm, sponsor-initiated pilot study will evaluate the clinical course and safety of MORA Cure in adults older than 50 years with knee osteoarthritis accompanied by anterior knee pain. Participants will use MORA Cure for 8 weeks. MORA Cure provides personalized rehabilitation exercises and cognitive behavioral therapy-based content through a patient mobile application supported by a clinician web portal. Clinical outcomes will be assessed at baseline, Week 4, and Week 8. The planned enrollment is 44 participants at two sites in the Republic of Korea.
Read the detailed description
The study includes a screening visit conducted within 4 weeks before baseline. The screening and baseline visits may occur on the same day; therefore, each participant will complete 3 or 4 outpatient visits. At baseline, the investigator will prescribe MORA Cure and assist with installation and initiation of the patient mobile application. Participants will use MORA Cure for 8 weeks, perform personalized rehabilitation exercises at least 3 times per week for approximately 30 minutes per session, and complete cognitive behavioral therapy content according to weekly sessions.
Assessments include usual and worst overall knee pain, usual and worst anterior knee pain using a 0-100 visual analog scale, the Knee injury and Osteoarthritis Outcome Score, the Anterior Knee Pain Scale (Kujala), the 30-second Sit-to-Stand Test, EQ-5D-5L and EQ-VAS, the Patient Health Questionnaire-9, the Pain Catastrophizing Scale, participant satisfaction, the System Usability Scale, and adverse events. Body weight and exercise performed outside MORA Cure are collected as exploratory factors.
This is a single-arm exploratory pilot study without a comparator group. Accordingly, observed changes cannot distinguish the effect of MORA Cure from natural improvement or other time-related factors. The Week 8 change in usual overall knee pain is designated as the primary outcome for registry organization only and will be interpreted as a principal exploratory outcome, not as confirmatory evidence of efficacy.
- Conditions
- Knee Osteoarthritis, Anterior Knee Pain
- Being tested
- MORA Cure
- Keywords
- MORA Cure, Everex, Personalized Rehabilitation Exercise, Knee Pain
- Medical subject headings
- Osteoarthritis, Knee
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MORA CureDevice
MORA Cure consists of a clinician web program (ETH-01KW) and a patient mobile application (ETH-01K). At baseline, the investigator registers the participant and issues a prescription code. The participant installs the application and uses it for 8 weeks. The application collects symptom information and AI-based movement assessment results, provides personalized rehabilitation exercises at least 3 times per week for approximately 30 minutes per session, adjusts exercise load based on participant data, and provides weekly cognitive behavioral therapy content. The application is deleted at Week 8.
| Study group | Role | What they receive |
|---|---|---|
| Experimental: MORA Cure | Experimental | Participants will use MORA Cure for 8 weeks. Personalized rehabilitation exercises are performed at least 3 times per week for approximately 30 minutes per session, and cognitive behavioral therapy content is completed according to weekly sessions. Receives: Device: MORA Cure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Usual Overall Knee Pain Assessed by Visual Analog Scale at Week 8
Participants rate the average pain in the study knee over the previous 7 days on a 0-100 visual analog scale, where 0 indicates no pain and 100 indicates the worst imaginable pain. Change is calculated as the Week 8 score minus the baseline score; negative values indicate improvement.
Measured: Baseline and Week 8
Secondary outcomes (4)
Change From Baseline in Usual Overall Knee Pain Assessed by Visual Analog Scale at Week 4
Same 0-100 scale and scoring direction as the primary outcome. Change is Week 4 minus baseline; negative values indicate improvement.
Measured: Baseline and Week 4
Change From Baseline in Worst Overall Knee Pain Assessed by Visual Analog Scale
Worst pain in the study knee over the previous 7 days is rated on a 0-100 visual analog scale, where higher scores indicate worse pain. Negative change indicates improvement.
Measured: Baseline, Week 4, and Week 8
Change From Baseline in Usual Anterior Knee Pain Assessed by Visual Analog Scale
Average pain over the previous 7 days in the peripatellar, anterior patellar, or retropatellar region is rated on a 0-100 visual analog scale. Higher scores indicate worse pain; negative change indicates improvement
Measured: Baseline, Week 4, and Week 8
Change From Baseline in Worst Anterior Knee Pain Assessed by Visual Analog Scale
Worst anterior knee pain over the previous 7 days is rated on a 0-100 visual analog scale. Higher scores indicate worse pain; negative change indicates improvement.
Measured: Baseline, Week 4, and Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2026
- Study start10 Jul 2026
- Primary completion10 Sep 2026 (estimated)
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Knee OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Open-label, single-arm study
- Masking
- None (open label)
- Enrolment
- 44 participants (estimated)
Sponsor and investigators
- Lead sponsor
- EverEx Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07769593
- Sponsor's protocol ID
- EX-CU-KO-03
- Acronym
- Leave blank
- Status last verified
- Aug 2026
- First submitted
- 13 Aug 2026
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Complete only if Yes
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multicenter, Single-Arm, Pilot Study to Evaluate the Clinical Outcomes and Safety of the Digital Therapeutic MORA Cure in Patients With Knee Osteoarthritis Accompanied by Anterior Knee Pain: 8-week
- ClinicalTrials.gov ID
- NCT07769593
- Acronym / sponsor ID
- Leave blank / EX-CU-KO-03
- Conditions
- Knee Osteoarthritis, Anterior Knee Pain
- Keywords
- MORA Cure, Everex, Personalized Rehabilitation Exercise, Knee Pain
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 44 participants (estimated)
- Lead sponsor
- EverEx Inc.Industry (pharma, biotech, devices)
- Study start
- 10 Jul 2026 (actual)
- Primary completion
- 10 Sep 2026 (estimated)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 18 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, multicenter, single-arm, sponsor-initiated pilot study will evaluate the clinical course and safety of MORA Cure in adults older than 50 years with knee osteoarthritis accompanied by anterior knee pain. Participants will use MORA Cure for 8 weeks. MORA Cure provides personalized rehabilitation exercises and cognitive behavioral therapy-based content through a patient mobile application supported by a clinician web portal. Clinical outcomes will be assessed at baseline, Week 4, and Week 8. The planned enrollment is 44 participants at two sites in the Republic of Korea.
Detailed description
The study includes a screening visit conducted within 4 weeks before baseline. The screening and baseline visits may occur on the same day; therefore, each participant will complete 3 or 4 outpatient visits. At baseline, the investigator will prescribe MORA Cure and assist with installation and initiation of the patient mobile application. Participants will use MORA Cure for 8 weeks, perform personalized rehabilitation exercises at least 3 times per week for approximately 30 minutes per session, and complete cognitive behavioral therapy content according to weekly sessions.
Assessments include usual and worst overall knee pain, usual and worst anterior knee pain using a 0-100 visual analog scale, the Knee injury and Osteoarthritis Outcome Score, the Anterior Knee Pain Scale (Kujala), the 30-second Sit-to-Stand Test, EQ-5D-5L and EQ-VAS, the Patient Health Questionnaire-9, the Pain Catastrophizing Scale, participant satisfaction, the System Usability Scale, and adverse events. Body weight and exercise performed outside MORA Cure are collected as exploratory factors.
This is a single-arm exploratory pilot study without a comparator group. Accordingly, observed changes cannot distinguish the effect of MORA Cure from natural improvement or other time-related factors. The Week 8 change in usual overall knee pain is designated as the primary outcome for registry organization only and will be interpreted as a principal exploratory outcome, not as confirmatory evidence of efficacy.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Open-label, single-arm study
| Arm | Type | Receives |
|---|---|---|
| Experimental: MORA Cure | Experimental | Device: MORA CureParticipants will use MORA Cure for 8 weeks. Personalized rehabilitation exercises are performed at least 3 times per week for approximately 30 minutes per session, and cognitive behavioral therapy content is completed according to weekly sessions. |
Who may qualify
- Ages
- 51 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adults older than 50 years.
- Kellgren-Lawrence grade 1 or higher on weight-bearing plain radiographs of the study knee.
- Osteoarthritis-related pain in the study knee for at least 3 months.
- Anterior knee pain in the study knee involving the peripatellar, anterior patellar, or retropatellar region, with clear provocation or worsening of anterior knee pain during at least one patellofemoral joint-loading activity: stair ascent or descent, squatting, or rising from a chair.
- If medial, lateral, or posterior knee pain is also present, the participant is able to distinguish and separately report anterior knee pain.
Key exclusion criteria (9 listed)
- Acute injury of the study knee within the previous 3 months, including fracture, ligament tear, or meniscal tear requiring surgical treatment or immobilization.
- Injection therapy to the study knee within the previous 3 months.
- Current use of opioid analgesics for pain control.
- Does not own a smartphone or is unable to use the mobile application.
- Current participation in another clinical trial or planned participation in another clinical trial during this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MORA CureMORA Cure consists of a clinician web program (ETH-01KW) and a patient mobile application (ETH-01K). At baseline, the investigator registers the participant and issues a prescription code. The participant installs the application and uses it for 8 weeks. The application collects symptom information and AI-based movement assessment results, provides personalized rehabilitation exercises at least 3 times per week for approximately 30 minutes per session, adjusts exercise load based on participant data, and provides weekly cognitive behavioral therapy content. The application is deleted at Week 8. | Device | Experimental: MORA Cure |
Primary outcome
Change From Baseline in Usual Overall Knee Pain Assessed by Visual Analog Scale at Week 8
Time frame: Baseline and Week 8
Participants rate the average pain in the study knee over the previous 7 days on a 0-100 visual analog scale, where 0 indicates no pain and 100 indicates the worst imaginable pain. Change is calculated as the Week 8 score minus the baseline score; negative values indicate improvement.
4 secondary outcomes
Change From Baseline in Usual Overall Knee Pain Assessed by Visual Analog Scale at Week 4
Time frame: Baseline and Week 4
Change From Baseline in Worst Overall Knee Pain Assessed by Visual Analog Scale
Time frame: Baseline, Week 4, and Week 8
Change From Baseline in Usual Anterior Knee Pain Assessed by Visual Analog Scale
Time frame: Baseline, Week 4, and Week 8
Change From Baseline in Worst Anterior Knee Pain Assessed by Visual Analog Scale
Time frame: Baseline, Week 4, and Week 8
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
- Individual participant dataSharing planned: No. Complete only if Yes
Related trials for Knee Osteoarthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MORA Cure in people with Knee Osteoarthritis and Anterior Knee Pain, run by EverEx Inc. at 2 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Usual Overall Knee Pain Assessed by Visual Analog Scale at Week 8 (time frame: Baseline and Week 8). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.